Study 309/Keynote-775: A Randomized, Phase 3 Study to Compare the Efficacy and Safety of Lenvatinib with Pembrolizumab vs Treatment of Physician’s Choice in Advanced Endometrial Cancer-Presentation Recording

Video Transcription

Video Summary

In this video, the speaker, a GYN Medical Oncologist at Memorial Sloan Kettering Cancer Center, presents on a study comparing the efficacy and safety of Linvatinib and Pembrolizumab versus treatment of physician's choice in advanced endometrial cancer. The study found that the combination of Linvatinib and Pembrolizumab showed significant improvements in objective response rate, progression-free survival, and overall survival compared to treatment of physician's choice. These benefits were observed across all analyzed subgroups, including histology and number of prior therapies. The regimen had a manageable safety profile, with common adverse events including hypertension, hypothyroidism, diarrhea, nausea, and decreased appetite. The speaker emphasizes the importance of early patient education, thorough discussion of the management plan for common toxicities, pre-treatment optimization of comorbidities, and regular laboratory assessments. They also highlight the benefits of a multidisciplinary team approach and proactive management of adverse events. Finally, the speaker reminds viewers that the recording of the session will be available on the IGCS education portal, and invites them to the upcoming IGCS annual global meeting.

Keywords

Linvatinib

Pembrolizumab

endometrial cancer

objective response rate

progression-free survival

adverse events

multidisciplinary team approach